JP2022532098A5 - - Google Patents
Info
- Publication number
- JP2022532098A5 JP2022532098A5 JP2021566041A JP2021566041A JP2022532098A5 JP 2022532098 A5 JP2022532098 A5 JP 2022532098A5 JP 2021566041 A JP2021566041 A JP 2021566041A JP 2021566041 A JP2021566041 A JP 2021566041A JP 2022532098 A5 JP2022532098 A5 JP 2022532098A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cd49d
- limb
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901540A AU2019901540A0 (en) | 2019-05-06 | Therapeutic uses and methods | |
| AU2019901540 | 2019-05-06 | ||
| PCT/AU2020/050445 WO2020223762A1 (en) | 2019-05-06 | 2020-05-06 | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532098A JP2022532098A (ja) | 2022-07-13 |
| JP2022532098A5 true JP2022532098A5 (https=) | 2023-05-16 |
Family
ID=73050454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566041A Ceased JP2022532098A (ja) | 2019-05-06 | 2020-05-06 | ＣＤ４９ｄに対する阻害オリゴヌクレオチドを使用して筋ジストロフィーを治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220296631A1 (https=) |
| EP (1) | EP3965778A4 (https=) |
| JP (1) | JP2022532098A (https=) |
| KR (1) | KR20220061915A (https=) |
| CN (1) | CN114555095A (https=) |
| AU (1) | AU2020269078A1 (https=) |
| BR (1) | BR112021022208A2 (https=) |
| CA (1) | CA3138945A1 (https=) |
| WO (1) | WO2020223762A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100014333A1 (it) * | 2021-06-01 | 2022-12-01 | Materias S R L | Nuovo impiego terapeutico di inibitori della iodiotironina deiodinasi di tipo 2 (D2) |
| WO2024159266A1 (en) * | 2023-02-01 | 2024-08-08 | Antisense Therapeutics Ltd | Combination compositions and methods for treatment of muscular dystrophy |
| CN119113214B (zh) * | 2024-11-14 | 2025-02-11 | 四川大学 | 一种肌肉修复材料及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2318424B1 (en) * | 2008-06-23 | 2015-02-25 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| JP5931720B2 (ja) * | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
| EP2467159A1 (en) * | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| EP3858993A1 (en) * | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| AU2018286483C1 (en) * | 2017-06-16 | 2024-10-31 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| KR20210018820A (ko) * | 2018-05-04 | 2021-02-18 | 안티센스 테라퓨틱스 엘티디 | 치료 용도 및 방법 |
-
2020
- 2020-05-06 BR BR112021022208A patent/BR112021022208A2/pt unknown
- 2020-05-06 JP JP2021566041A patent/JP2022532098A/ja not_active Ceased
- 2020-05-06 CA CA3138945A patent/CA3138945A1/en active Pending
- 2020-05-06 CN CN202080049373.1A patent/CN114555095A/zh active Pending
- 2020-05-06 KR KR1020217039906A patent/KR20220061915A/ko not_active Ceased
- 2020-05-06 AU AU2020269078A patent/AU2020269078A1/en active Pending
- 2020-05-06 EP EP20801736.8A patent/EP3965778A4/en not_active Withdrawn
- 2020-05-06 WO PCT/AU2020/050445 patent/WO2020223762A1/en not_active Ceased
- 2020-05-06 US US17/609,334 patent/US20220296631A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532098A5 (https=) | ||
| US20160201064A1 (en) | Compositions and methods for modulating expression of frataxin | |
| EP2442832B1 (en) | Compositions and methods for treatment of multiple sclerosis | |
| JP2014507143A (ja) | アンチセンスオリゴヌクレオチド | |
| JP2000511561A (ja) | 肥満症の処置のためのｃｎｔｆ（毛様体神経成長因子）受容体アクティベーターの使用 | |
| JP2022536495A5 (https=) | ||
| JP2023520469A5 (https=) | ||
| CN103079597A (zh) | 包含反义寡核苷酸的药物组合物及其使用方法 | |
| AU2022341090B2 (en) | Treatment of neurological disorders | |
| EP3148549A1 (en) | Fatty acid bile acid conjugates for treatment of lipodystrophy | |
| KR20220061915A (ko) | Cd49d에 대한 억제성 올리고뉴클레오티드를 사용하는 근이영양증의 치료 방법 | |
| US20250223591A1 (en) | Syf2 antisense oligonucleotides | |
| CN110636847A (zh) | 用于预防及治疗肌肉疾病的组合物 | |
| EP4658787A2 (en) | Syf2 antisense oligonucleotides | |
| US20230019602A1 (en) | Methods for treatment of motor neuron diseases | |
| JP2013503908A5 (https=) | ||
| JP2024506041A (ja) | 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド | |
| US20250213494A1 (en) | Methods and compositions for potentiation of a ligand | |
| US20210186950A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| US20240277641A1 (en) | Methods for treating nervous system disorders with antipurinergic agents | |
| TW201932114A (zh) | 化合物用於炎症介導的視神經病變的治療 | |
| WO2020146477A1 (en) | Treatment of fatty liver disease | |
| CN120322429A (zh) | 基于维生素的脂质以及包含其的脂质纳米颗粒 | |
| HK40113386A (zh) | 神经病症的治疗 | |
| HK1167101B (en) | Compositions and methods for treatment of multiple sclerosis |